- All
- Important
- Financial Update
- Fund Raise
- Board Meeting
- Dividend/Bonus
- JV/Acquisition
- Investor Meet
- Insider Trade
- Pledging
- Others
AstraZeneca Pharma India Limited — Important, 01-07-2025: Updates
01-07-2025 | 07:04 pm
01-07-2025 | 07:04 pm
AstraZeneca Pharma India has announced a board meeting to discuss the financial results for the quarter and half-year. The company received approval to import and market Durvalumab (Imfinzi) for an additional indication related to advanced or recurrent endometrial cancer, enabling broader treatment options. This development could enhance its oncology portfolio and market presence in India.
No comments yet. Be the first to comment!